Merus exploits three proprietary and complementary technology platforms for the discovery and development of next-generation antibody therapeutics. MeMo® is a state-of-the-art transgenic mouse that produces single light chain (sLC) human antibodies upon immunization. sLC human antibodies constitute the basis for bispecific antibodies and Oligoclonics™ [antibody mixtures] that are capable of binding to multiple different epitopes on a target antigen and/or simultaneously addressing multiple targets.
